Clinical Trials Learning Sessions
PHEN provides Clinical Trial Learning Sessions in conjunction with cancer centers to bring Black patients and clinical trial doctors together to learn about clinical trials, and to build trust around clinical trial participation.
Understanding Omaha-003 and Omaha-004 Clinical Trials
Learn about emerging clinical trial options for metastatic castration-resistant prostate cancer (mCRPC) in this fireside chat featuring Keith Crawford, MD, PhD, Director of Clinical Trials and Patient Education, PHEN and Pedro Barata, MD, Director of the GU Medical Oncology Research Program at University Hospitals Seidman Cancer Center.
This discussion explores the Omaha-003 and Omaha-004 clinical trials, including how these investigational treatments work to block hormones that help prostate cancer grow, the differences between the studies, and who may qualify to participate.
Topics Covered:
• Overview of metastatic castration-resistant prostate cancer (mCRPC)
• How investigational hormone-blocking therapies work
• Key differences between the Omaha-003 and Omaha-004 clinical trials
• Eligibility criteria and what participation may involve
• The role of clinical trials in advanced prostate cancer treatment
Understanding XALute Clinical Trial
The XALUTE clinical trial, sponsored by Bayer, is a research study evaluating an investigational treatment approach for prostate cancer, designed to assess safety and effectiveness while providing eligible patients access to innovative therapy options under closely monitored clinical care.
Understanding ARASTEP Clinical Trial
The ARASTEP clinical trial, sponsored by Bayer in collaboration with PHEN, is a prostate cancer research study evaluating whether the combination of darolutamide and androgen deprivation therapy (ADT) can delay disease progression in patients experiencing biochemical recurrence, with expert insights from Dr. Keith Crawford and Dr. Emmanuel S. Antonarakis to help patients with rising PSA levels understand eligibility, benefits, and participation in this important clinical trial.
Understanding EZH2 Clinical Trial
In collaboration with Pfizer, PHEN hosted a clinical trial learning session highlighting three coordinated Phase 3 studies evaluating a twice-daily oral EZH2 inhibitor added to standard-of-care treatment for men with metastatic castration-resistant prostate cancer (mCRPC), exploring whether combining the investigational therapy with agents such as enzalutamide can delay treatment resistance and slow disease progression, with expert insights from Dr. Keith Crawford and Dr. Neal Shore on eligibility, study design, side effects, and the importance of diverse participation.
Duke Cancer Institute
Clinical Trials Learning Session
Duke Cancer Institute physicians and the Prostate Health Education Network (PHEN) present a virtual session to learn about clinical trial opportunities available at Duke.
Johns Hopkins University
Clinical Trials Learning Session
Physicians from the Johns Hopkins University School of Medicine partner with PHEN to hold a virtual webinar and discuss clinical trial opportunities found at Johns Hopkins.
MSKCC
Clinical Trials Learning Session
Memorial Sloan Kettering Cancer Center’s physicians partnered with PHEN to present a virtual learning session about clinical trial opportunities available at MSKCC.
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.